CVRx Reports Barostim CMS Reimbursement Updates

July 16, 2025—CVRx, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the company’s Barostim implantation procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting.

CVRx advised that CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. The company anticipates CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System final rule in November, which is expected to take effect on January 1, 2026.

The company also noted that in October 2024, it announced that Barostim was assigned to a higher paying MS-DRG for inpatient procedures and that Barostim will transition from Category III to Category I CPT codes for physician payments as of January 1, 2026.

According to CVRx, Barostim uses neuromodulation to reduce the symptoms of heart failure. The implanted device, which has received FDA approval, delivers electrical pulses to baroreceptors located in the wall of the carotid artery to restore balance to the autonomic nervous system.

In Europe, Barostim has been certified as compliant with the European Union Medical Device Regulation and received CE Mark approval for heart failure and resistant hypertension, stated the company.